New drug may reduce need for plasma exchange in rare blood disorder
NCT ID NCT05714969
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 28 times
Summary
This study tested a drug called TAK-755 in 29 adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare condition causing dangerous blood clots. The goal was to see if TAK-755, along with standard immune-suppressing drugs, could help patients recover without needing plasma exchange (a procedure to filter the blood). Participants received TAK-755 during an acute attack and for up to 6 weeks afterward, with the study lasting about 3 months. The main focus was on safety and whether the drug could normalize platelet counts and prevent organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AKH - Medizinische Universitat Wien
Vienna, 1090, Austria
-
Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino
Torino, 10126, Italy
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
Milan, 20122, Italy
-
General Hospital of Thessaloniki "G. Papanikolaou"
Thessaloniki, 57010, Greece
-
Hospital General Universitario Gregorio Maranon
Madrid, 28007, Spain
-
Hospital Universitari i Politecnic La Fe
Valencia, 46026, Spain
-
Hospital Universitario Virgen del Rocio
Seville, Sevilla, 41010, Spain
-
Hospital de Cruces
Barakaldo, Vizcaya, 48903, Spain
-
Leo Jenkins Cancer Center/ECU School of Medicine
Greenville, North Carolina, 27858, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Royal Liverpool University Hospital
Liverpool, Merseyside, L7 8XP, United Kingdom
-
Rutgers University
New Brunswick, New Jersey, 08901, United States
-
University College London Hospital
London, Greater London, NW1 2PG, United Kingdom
-
University of Florida - Shands
Gainesville, Florida, 32610, United States
-
University of Minnesota Clinical Research Unit
Minneapolis, Minnesota, 55455, United States
-
University of Utah Health Sciences Center
Salt Lake City, Utah, 84132, United States
-
Versiti Wisconsin, Inc.
Milwaukee, Wisconsin, 53226, United States
-
Weill Cornell
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.